Peer-reviewed veterinary case report
Intranasal live canine flu vaccine protects beagles better than shot
By Hwang, Jaehyun et al.·Published in Veterinary research·2025·College of Veterinary Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intranasal NS1-truncated live attenuated canine influenza vaccine confers superior protection compared to inactivated vaccine in beagles.
- Species:
- dog
Plain-English summary
A group of beagle dogs was vaccinated with a new intranasal canine influenza vaccine and then exposed to the virus to see how well it worked. The new vaccine was well-tolerated and provided strong protection, with vaccinated dogs showing no signs of illness and very little virus in their systems. In contrast, dogs that received the traditional inactivated vaccine experienced moderate symptoms. This new vaccine could be a better option for protecting dogs against canine influenza.
People also search for: beagle dog flu vaccine · canine influenza symptoms · best vaccine for dog flu
Abstract
Canine influenza virus (CIV) H3N2 continues to circulate among companion animals, posing a zoonotic risk due to its potential for cross-species transmission. However, currently available inactivated vaccines offer limited mucosal immunity and suboptimal protection. Here, we developed a novel intranasal live attenuated CIV H3N2 vaccine carrying a truncated nonstructural protein 1 (NS1) gene and evaluated its safety, immunogenicity, and protective efficacy in beagle dogs. The NS1-truncated LAIV was well-tolerated and induced robust mucosal and systemic immune responses, including high titers of virus-specific secretory IgA. Following challenge with virulent CIV H3N2 at 120 days post-vaccination, LAIV-immunized dogs exhibited complete clinical protection and minimal viral shedding, whereas dogs receiving the inactivated vaccine showed moderate disease signs. These findings demonstrate that the NS1-truncated LAIV confers superior protection compared to conventional vaccines and represents a promising next-generation platform for canine influenza control within a One Health framework.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40999547/